Qyuns Therapeutics Co (HKSE:02509) Other Stockholders Equity: HK$733 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$16.24
! 6 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co Other Stockholders Equity?

Qyuns Therapeutics Co HKSE:02509 -1.10% 9 Other Stockholders Equity is HK$733 Mil as of Jun. 2026. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Qyuns Therapeutics Co's Other Stockholders Equity for the quarter that ended in Jun. 2026 was HK$733 Mil.

Qyuns Therapeutics Co's quarterly Other Stockholders Equity increased from Jun. 2025 (HK$303 Mil) to Dec. 2025 (HK$374 Mil) and increased from Dec. 2025 (HK$374 Mil) to Jun. 2026 (HK$733 Mil).

Qyuns Therapeutics Co's annual Other Stockholders Equity increased from Dec. 2023 (HK$192 Mil) to Dec. 2024 (HK$268 Mil) and increased from Dec. 2024 (HK$268 Mil) to Dec. 2025 (HK$374 Mil).

Qyuns Therapeutics Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Qyuns Therapeutics Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co Other Stockholders Equity Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
3.75 49.82 192.41 268.38 373.61

Qyuns Therapeutics Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only 243.89 268.38 302.87 373.61 733.30
HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$733 Mil mean?
Qyuns Therapeutics Co (HKSE:02509) has a Other Stockholders Equity of HK$733 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Qyuns Therapeutics Co and its competitors.
Is Qyuns Therapeutics Co's Other Stockholders Equity too high?
Qyuns Therapeutics Co's current Other Stockholders Equity is HK$733 Mil. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Other Stockholders Equity compare to VRTX and REGN?
Qyuns Therapeutics Co's Other Stockholders Equity of HK$733 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Qyuns Therapeutics Co and its competitors. Qyuns Therapeutics Co's current Other Stockholders Equity is HK$733 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Other Stockholders Equity of HK$733 Mil. The current Other Stockholders Equity is HK$733 Mil. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Other Stockholders Equity is HK$733 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.24
Price